Vascular Malformations
A spectrum of congenital, inherited, or acquired abnormalities in BLOOD VESSELS that can adversely affect the normal blood flow in ARTERIES or VEINS. Most are congenital defects such as abnormal communications between blood vessels (fistula), shunting of arterial blood directly into veins bypassing the CAPILLARIES (arteriovenous malformations), formation of large dilated blood blood-filled vessels (cavernous angioma), and swollen capillaries (capillary telangiectases). In rare cases, vascular malformations can result from trauma or diseases.
Subtype terms (13)
More specific conditions that are subtypes of Vascular Malformations in the MeSH hierarchy.
- Arterio-Arterial Fistula
- Arteriovenous Malformations
15 drugs (13 approved, 2 experimental)
- Central Nervous System Vascular Malformations
- Congenital Portosystemic Shunt
- May-Thurner Syndrome
4 drugs (3 approved, 1 experimental)
- Median Arcuate Ligament Syndrome
- Persistent Left Superior Vena Cava
- Pulmonary Atresia
2 drugs (1 approved, 1 experimental)
- Scimitar Syndrome
- Single Umbilical Artery
- Telangiectasia, Hereditary Hemorrhagic
19 drugs (15 approved, 4 experimental)
- Vascular Fistula
- Vascular Ring
1 drug approved
Drugs by status
Phase 3 trials (3)
Phase 2 trials (7)
Other trials (1)
Organizations
Organization Involved with Phase 3 Indications (21)
- Galderma
- Guangzhou Bioseal Biotechnology Co., Ltd.
- Ethicon
- Maastricht University
- Hebei University
- Changhai Hospital
- Jeroen Bosch Ziekenhuis
- Radboud University
- Reinier de Graaf Groep
- University of Toronto
- Fudan University
- Université catholique de Louvain
- Tsinghua University
- Free University of Amsterdam
- Jiao Tong University
- Southern Medical University
- St. Antonius Hospital, Nieuwegein
- Elisabeth-TweeSteden Ziekenhuis
- Gelre Hospitals
- Bernhoven
- People's Liberation Army of China
Organization Involved with Phase 2 Indications (9)
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (2)